2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

NASDAQ:TSVT

2seventy bio

Last Close

4.57

26/07 20:00

Market Cap

197.91M

Beta: -

Volume Today

329.50K

Avg: 949.59K

PE Ratio

−1.62

PFCF: −1.64

Filings Not Available